The Israeli Teva Pharmaceutical Industries announced that it has launched a purchase offer for all outstanding shares of the American company Mylan. $82 per share was placed on the plate, half in cash and half in shares, for a total that gives a monstrous figure: over $31 billion.
This is a 37,7% premium to the share price Mylan to last April 7, the day before the launch by Mylan of a purchase offer on the Irishman Perrigo. Compared to last March 10, the last day of trading before the rumors of a possible transaction between Teva and Mylan began, the premium is 48,3%.
Today Teva is among the top 15 most important pharmaceutical companies in the world and among the global leaders in the production of generic medicines, operates in 60 countries around the world and has over 46.000 employees.
This operation confirms the particularly lively moment of the pharmaceutical sector, for a year now, after Pfizer's assault on AstraZeneca and the merger, in Italy, between Alfa Wassermann and Sigma-Tau.
